Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP238631.RA5k9Y_0fN9UTRiMN0E7ZXqsFXmaHIu3Amja2FKousf7E130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP238631.RA5k9Y_0fN9UTRiMN0E7ZXqsFXmaHIu3Amja2FKousf7E130_assertion type Assertion NP238631.RA5k9Y_0fN9UTRiMN0E7ZXqsFXmaHIu3Amja2FKousf7E130_head.
- NP238631.RA5k9Y_0fN9UTRiMN0E7ZXqsFXmaHIu3Amja2FKousf7E130_assertion wasGeneratedBy ECO_0000203 NP238631.RA5k9Y_0fN9UTRiMN0E7ZXqsFXmaHIu3Amja2FKousf7E130_provenance.
- NP238631.RA5k9Y_0fN9UTRiMN0E7ZXqsFXmaHIu3Amja2FKousf7E130_assertion wasDerivedFrom befree-20140225 NP238631.RA5k9Y_0fN9UTRiMN0E7ZXqsFXmaHIu3Amja2FKousf7E130_provenance.
- NP238631.RA5k9Y_0fN9UTRiMN0E7ZXqsFXmaHIu3Amja2FKousf7E130_assertion SIO_000772 19833260 NP238631.RA5k9Y_0fN9UTRiMN0E7ZXqsFXmaHIu3Amja2FKousf7E130_provenance.
- NP238631.RA5k9Y_0fN9UTRiMN0E7ZXqsFXmaHIu3Amja2FKousf7E130_assertion evidence source_evidence_literature NP238631.RA5k9Y_0fN9UTRiMN0E7ZXqsFXmaHIu3Amja2FKousf7E130_provenance.
- NP238631.RA5k9Y_0fN9UTRiMN0E7ZXqsFXmaHIu3Amja2FKousf7E130_assertion description "[We defined a composite adverse event (CAE) as discontinuation for any side effect, myalgia, or CK >3x upper limit of normal during follow-up.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP238631.RA5k9Y_0fN9UTRiMN0E7ZXqsFXmaHIu3Amja2FKousf7E130_provenance.